Payment overview · 2025
General Payments
$179,660.57
235 reported records · 10 companies
Healthcare provider profile · identity verified
Atman Shah
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · CHICAGO, IL · NPI 1033138557
Verified facts
What the public records show
CMS Open Payments records show Atman Shah received $179,660.57 in general payments during 2025 across 235 reported records.
Abbott Laboratories accounted for 98.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $176,156.95 | 98.0% | 211 | 2025 |
| Maquet Cardiovascular L.L.C. | Unresolved — no canonical attribution shown | $2,100.00 | 1.2% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $1,049.70 | 0.6% | 8 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $175.88 | 0.1% | 7 | 2025 |
| Inari Medical, Inc. | Unresolved — no canonical attribution shown | $47.43 | 0.0% | 2 | 2025 |
| Acist Medical Systems, Inc. | Unresolved — no canonical attribution shown | $32.62 | 0.0% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $32.19 | 0.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.59 | 0.0% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$21.59 | 0.0% | 1 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $20.62 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $127,037.50 | 27 |
| Travel and Lodging | $32,535.55 | 87 |
| Compensation for serving as faculty or as a speaker for a medical education program | $15,743.75 | 9 |
| Food and Beverage | $4,343.77 | 112 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AMPLATZER AMULET Normalized: amplatzer amulet |
Device | Abbott Laboratories | $146,560.72 | 160 | 2025 |
Source payment records
|
|||||
| NAVITOR Normalized: navitor |
Device | Abbott Laboratories | $25,552.70 | 42 | 2025 |
Source payment records
|
|||||
| AMPLATZER TALISMAN Normalized: amplatzer talisman |
Device | Abbott Laboratories | $3,873.88 | 4 | 2025 |
Source payment records
|
|||||
| VASOVIEW HEMOPRO 2 Normalized: vasoview hemopro 2 |
Device | Maquet Cardiovascular L.L.C. | $2,100.00 | 1 | 2025 |
Source payment records
|
|||||
| EVOQUE Normalized: evoque |
Device | Edwards Lifesciences Corporation | $790.86 | 7 | 2025 |
Source payment records
|
|||||
| MITRACLIP Normalized: mitraclip |
Device | Abbott Laboratories | $121.68 | 3 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Inari Medical, Inc., Stryker Corporation | $91.91 | 4 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Inari Medical, Inc., Stryker Corporation | $91.91 | 4 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER Normalized: flowtriever |
Device | Stryker Corporation | $79.01 | 3 | 2025 |
Source payment records
|
|||||
| ARTIX MT Normalized: artix mt |
Device | Stryker Corporation | $52.39 | 2 | 2025 |
Source payment records
|
|||||
| CVI Systems Normalized: cvi systems |
Device | Acist Medical Systems, Inc. | $32.62 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $32.19 | 2 | 2025 |
Source payment records
|
|||||
| OPTIS Normalized: optis |
Device | Abbott Laboratories | $24.01 | 1 | 2025 |
Source payment records
|
|||||
| AMPLATZER Normalized: amplatzer |
Device | Abbott Laboratories | $23.96 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $23.59 | 1 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $21.59 | 1 | 2025 |
Source payment records
|
|||||
| MANTA Normalized: manta |
Device | Teleflex LLC | $20.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 60 | 20 |
| Atorvastatin Calcium | Atorvastatin Calcium | 45 | 19 |
| Amlodipine Besylate | Amlodipine Besylate | 37 | 14 |
| Carvedilol | Carvedilol | 37 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 37 | 15 |
| Entresto | Sacubitril/Valsartan | 28 | 11 |
| Furosemide | Furosemide | 24 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 22 | suppressed |
| Eliquis | Apixaban | 20 | suppressed |
| Lisinopril | Lisinopril | 20 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Potassium Chloride | Potassium Chloride | 14 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Simvastatin | Simvastatin | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Losartan Potassium | Losartan Potassium | 12 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $179,660.57 · 235 records | Abbott Laboratories | AMPLATZER, AMPLATZER AMULET, AMPLATZER TALISMAN, ARTIX MT, CT THROMBECTOMY SYSTEM KIT, CVI Systems, EVOQUE, FLOWTRIEVER, FLOWTRIEVER CATHETER, S, LifeVest, MANTA, MITRACLIP, NAVITOR, OPTIS, SYMPLICITY G3, VASOVIEW HEMOPRO 2, VYNDAQEL | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error